权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Novel microfluidic platform for versatile, fast, low-cost DNA synthesis and assembly

用于多功能、快速、低成本 DNA 合成和组装的新型微流体平台

基本信息

批准号：
10268210
负责人：
Matthew Hill
金额：
$ 78.99万
依托单位：
ELEGEN CORPORATION
依托单位国家：
美国
项目类别：
财政年份：
2020
资助国家：
美国
起止时间：
2020-09-23 至 2023-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10268210
关键词：
Back Bypass Chemistry Clone Cells Confidential Information Coupling Custom DNA DNA biosynthesis Development Diagnostic tests Elements Ensure Evaluation Failure Genes Goals Government Hour Hybrids Industry Standard Label Laboratories Length Licensing Medical Methodology Microfluidics Microspheres Molecular Biology Nucleosides Oligonucleotides Patients Peptides Performance Persons Phase Positioning Attribute Procedures Process Protocols documentation Quality Control RNA Reaction Reporter Research Running Sales Scientist Services Site Solid Speed Stream Stretching Synthesis Chemistry System Technology Testing Time Vendor Vision base cost design flexibility innovation instrument machine vision manufacturing process novel novel diagnostics novel therapeutics operation phosphoramidite prototype quality assurance success synthetic biology synthetic construct vector

项目摘要

PROJECT SUMMARY Elegen Corporation proposes to develop a novel instrument that will quickly and inexpensively synthesize DNA. Elegen's approach exploits an innovative microfluidic platform, enabling us to create a simple benchtop system that can be deployed in the laboratory. Development of many biomedical applications – as well as the entire field of synthetic biology – typically involves iterating through a design-build-test loop requiring large quantities of custom synthetic DNA with every iteration. The turnaround time (TAT) between ordering and receiving DNA products from vendors can be several weeks and thus remains as the critical bottleneck in this loop. This long TAT severely impedes the pace of development of new diagnostics and therapeutics. Elegen's technology will shorten TAT from weeks to days by increasing flexibility in fulfilling orders and will also reduce cost. These improvements will have a transformative impact on research efficiency and will enable scientists to bring biomedical innovations to patients much faster than is currently possible. Elegen has already separately demonstrated all the key technology components needed to implement the proposed system. In this project, the company will integrate and optimize these components and demonstrate a fully-functional prototype system.

项目摘要 Elegen公司提议开发一种新型仪器， DNA. Elegen的方法利用了创新的微流体平台，使我们能够创建一个简单的工作台，该系统可以在实验室中部署。许多生物医学应用的发展-以及合成生物学的整个领域-通常涉及迭代设计-构建-测试循环，需要大量的大量定制的合成DNA订货和交货之间的周转时间（达特）从供应商那里收到DNA产品可能需要几周的时间，因此仍然是这方面的关键瓶颈。循环.这种长达特严重阻碍了新诊断和治疗的发展步伐。Elegen's 技术将通过提高履行订单的灵活性，将达特从数周缩短到数天，成本这些改进将对研究效率产生变革性影响，并使科学家能够将生物医学创新带给患者的速度比现在快得多。Elegen已经分别展示了实施拟议系统所需的所有关键技术组件。在本项目中，该公司将整合和优化这些组件，并展示一个功能齐全的原型系统